Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of three abstracts for a poster...
Truist Financial reiterated their buy rating on shares of Adicet Bio (NASDAQ:ACET – Free Report) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $27.00 price objective on the stock. Several other research firms have also weighed in on ACET. StockNews.com started coverage on shares of Adicet Bio in a […]
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on August 31,...
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report)’s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $5.24 and traded as low as $1.73. Adicet Bio shares last traded at $1.75, with a volume of 861,147 shares traded. Analyst […]
Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, Source of Cell, Target...